Beckman Coulter and IncellDx Sign Distribution Partnership to Benefit HPV Research in China, Hong Kong and Taiwan

Beckman Coulter Life Sciences and IncellDx, Inc have announced they have signed a distribution agreement which focuses exclusively on clinical researchers in China, Hong Kong and Taiwan working on the Human Papilloma Virus (HPV) and cancer.  The commercial partnership brings the power of multi-parameter flow cytometry to molecular testing, improving workflow while delivering sensitive and highly reliable cell identification.

IncellDx’s next generation (3Dx) investigational molecular assay used to quantify HPV E6, E7 mRNA in single cells has been specially optimised to run on Beckman Coulter’s innovative CytoFLEX flow cytometry system. The high throughput system instrument has the precision to integrate E6, E7 mRNA overexpression with the measurement of cell cycle and cell proliferation.

"The CytoFLEX easily fits into today’s rapid workflow in research cytometry – combining ease of use with exceptional analytical performance and built-in automation,” said Mario Koksch, Vice President and General Manager of the Beckman Coulter Flow Cytometry Business Unit. “This innovative partnership with IncellDx enables us to expand our product offerings in clinical research applications, further strengthening the company’s growing infectious diseases portfolio.”

Bruce Patterson MD, CEO of IncellDx commented: “We are excited about this opportunity to bring molecular testing to the flow cytometry field in a region of the world with a great appetite for innovation in the molecular space. The hallmark of cancer research is the quantification of oncogenes E6 and E7 in cells from the cervix, anus, or head and neck. However, as cytology samples contain a heterogeneous mixture of normal and abnormal cells, it is critical that we are able to carry out quantification at the single cell level.”